Echinocandin use in lung transplant recipients

Invasive fungal infections (IFI) are associated with significant morbidity and mortality in lung transplant recipients (LTRs). However, data outlining use of echinocandins in prophylaxis and therapy of LTRs are limited.

[1]  S. Husain,et al.  (621) – Role of Echinocandins as Antifungal Prophylaxis Agents in Lung Transplant Recipients , 2017 .

[2]  A. Muriel,et al.  Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high‐risk liver transplantation recipients: A propensity score analysis , 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[3]  A. Zaas,et al.  The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  S. Keshavjee,et al.  Survival in Sensitized Lung Transplant Recipients With Perioperative Desensitization , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  V. E. Zagaynov,et al.  Randomized Trial of Micafungin for the Prevention of Invasive Fungal Infection in High-Risk Liver Transplant Recipients , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Nina Singh,et al.  Randomized, Double‐Blind Trial of Anidulafungin Versus Fluconazole for Prophylaxis of Invasive Fungal Infections in High‐Risk Liver Transplant Recipients , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  B. Alexander,et al.  Epidemiology of Invasive Mold Infections in Lung Transplant Recipients , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  K. Mumtaz,et al.  Anti-Aspergillus Prophylaxis in Lung Transplantation: A Systematic Review and Meta-analysis , 2013, Current Infectious Disease Reports.

[9]  P. Camp,et al.  A Targeted Peritransplant Antifungal Strategy for the Prevention of Invasive Fungal Disease After Lung Transplantation: A Sequential Cohort Analysis , 2012, Transplantation.

[10]  P. Boutros,et al.  Risk Factors for Voriconazole Hepatotoxicity at 12 Weeks in Lung Transplant Recipients , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  G. Snell,et al.  Antifungal Prophylaxis in Lung Transplantation—A World‐wide Survey , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  V. Anttila,et al.  Control of early Aspergillus mortality after lung transplantation: outcome and risk factors. , 2010, Transplantation proceedings.

[13]  J. Michalek,et al.  Antifungal Prophylaxis with Voriconazole or Itraconazole in Lung Transplant Recipients: Hepatotoxicity and Effectiveness , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  R. Elashoff,et al.  Aspergillus Colonization of the Lung Allograft Is a Risk Factor for Bronchiolitis Obliterans Syndrome , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  R. Murray,et al.  Meta‐analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals , 2008, Transplant infectious disease : an official journal of the Transplantation Society.

[16]  D. Paterson,et al.  Variation in antifungal prophylaxis strategies in lung transplantation , 2006, Transplant infectious disease : an official journal of the Transplantation Society.

[17]  D. Pakstis,et al.  Voriconazole Prophylaxis in Lung Transplant Recipients , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  A. Glasmacher,et al.  Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. , 2006, The Journal of antimicrobial chemotherapy.

[19]  A. Solé,et al.  Aspergillus infections in lung transplant recipients: risk factors and outcome. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[20]  E. C. Lawrence,et al.  Review of patient outcomes of aspergillus prophylaxis with voriconazole after lung transplantation , 2005 .

[21]  G. Papanicolaou,et al.  Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A , 2004, Transplant infectious disease : an official journal of the Transplantation Society.

[22]  C. Solano,et al.  Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections , 2004, Bone Marrow Transplantation.

[23]  J. Chodakewitz,et al.  Safety and tolerability of caspofungin acetate in the treatment of fungal infections , 2002, Transplant infectious disease : an official journal of the Transplantation Society.